The Orthopaedics division of Contura aims to provide patients relief from the symptoms of
osteoarthritis, an area where current treatment options are limited and where it is
predicted that 10% of people over the age of 55 will suffer symptoms.

Arthrosamid fulfils the unmet clinical need for a long-acting, safe and minimally invasive
treatment that may prevent or postpone knee surgery.

Product image

Arthrosamid is a non-biodegradable hydrogel used for the treatment of symptomatic
osteoarthritis of the knee.

Once injected into the intra-articular cavity of the knee joint, Arthrosamid integrates
into the synovial tissue to provide long-lasting cushioning of the inner joint,
reducing pain and decreasing joint stiffness. Following the completion of a three-month
prospective open label study, which demonstrated significant pain reduction in patients
with osteoarthritis of the knee, Arthrosamid received European approval in 2020.

Latest news